Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: a systematic review and meta-analysis.

Kalil AC, Mindru C, Botha JF, Grant WJ, Mercer DF, Olivera MA, McCartan MA, McCashland TM, Langnas AN, Florescu DF.

Liver Transpl. 2012 Dec;18(12):1440-7. doi: 10.1002/lt.23530. Review.

2.

Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease.

Taber DJ, Ashcraft E, Baillie GM, Berkman S, Rogers J, Baliga PK, Rajagopalan PR, Lin A, Emovon O, Afzal F, Chavin KD.

Transpl Infect Dis. 2004 Sep;6(3):101-9.

PMID:
15569225
3.

Two strategies for prevention of cytomegalovirus infections after liver transplantation.

Simon P, Sasse M, Laudi S, Petroff D, Bartels M, Kaisers UX, Bercker S.

World J Gastroenterol. 2016 Mar 28;22(12):3412-7. doi: 10.3748/wjg.v22.i12.3412.

4.

Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis.

Kalil AC, Mindru C, Florescu DF.

Clin Infect Dis. 2011 Feb 1;52(3):313-21. doi: 10.1093/cid/ciq143. Epub 2010 Dec 28.

PMID:
21189424
5.

Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients.

Gabardi S, Asipenko N, Fleming J, Lor K, McDevitt-Potter L, Mohammed A, Rogers C, Tichy EM, Weng R, Lee RA.

Transplantation. 2015 Jul;99(7):1499-505. doi: 10.1097/TP.0000000000000570.

PMID:
25643140
6.

Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients.

Bodro M, Sabé N, Lladó L, Baliellas C, Niubó J, Castellote J, Fabregat J, Rafecas A, Carratalà J.

Liver Transpl. 2012 Sep;18(9):1093-9. doi: 10.1002/lt.23460.

7.

Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients.

Fayek SA, Mantipisitkul W, Rasetto F, Munivenkatappa R, Barth RN, Philosophe B.

HPB (Oxford). 2010 Dec;12(10):657-63. doi: 10.1111/j.1477-2574.2010.00226.x.

8.

Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis.

Shiley KT, Gasink LB, Barton TD, Pfeiffenberger P, Olthoff KM, Blumberg EA.

Liver Transpl. 2009 Aug;15(8):963-7. doi: 10.1002/lt.21769.

9.

Delayed-onset primary cytomegalovirus disease after liver transplantation.

Arthurs SK, Eid AJ, Pedersen RA, Dierkhising RA, Kremers WK, Patel R, Razonable RR.

Liver Transpl. 2007 Dec;13(12):1703-9.

10.

The role of secondary cytomegalovirus prophylaxis for kidney and liver transplant recipients.

Sullivan T, Brodginski A, Patel G, Huprikar S.

Transplantation. 2015 Apr;99(4):855-9. doi: 10.1097/TP.0000000000000386.

PMID:
25208322
11.

Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.

Park JM, Lake KD, Arenas JD, Fontana RJ.

Liver Transpl. 2006 Jan;12(1):112-6. Erratum in: Liver Transpl. 2006 Mar;12(3):494.

12.

Valganciclovir-induced leukopenia in liver transplant recipients: influence of concomitant use of mycophenolate mofetil.

Molina Perez E, Fernández Castroagudín J, Seijo Ríos S, Mera Calviño J, Tomé Martínez de Rituerto S, Otero Antón E, Bustamante Montalvo M, Varo Perez E.

Transplant Proc. 2009 Apr;41(3):1047-9. doi: 10.1016/j.transproceed.2009.02.033.

PMID:
19376423
13.

Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?

Jain A, Orloff M, Kashyap R, Lansing K, Betts R, Mohanka R, Menegus M, Ryan C, Bozorgzadeh A.

Transplant Proc. 2005 Sep;37(7):3182-6.

PMID:
16213344
14.

Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis.

Gabardi S, Magee CC, Baroletti SA, Powelson JA, Cina JL, Chandraker AK.

Pharmacotherapy. 2004 Oct;24(10):1323-30.

PMID:
15628830
16.

Efficacy and Safety of Low-Dose Versus Standard-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Intermediate-Risk Kidney Transplant Recipients.

Halim MA, Al-Otaibi T, Gheith O, Adel H, Mosaad A, Hasaneen AA, Zakaria Z, Makkeya Y, Said T, Nair P.

Exp Clin Transplant. 2016 Oct;14(5):526-534. doi: 10.6002/ect.2015.0305. Epub 2016 Jun 15.

17.

Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil.

Brum S, Nolasco F, Sousa J, Ferreira A, Possante M, Pinto JR, Barroso E, Santos JR.

Transplant Proc. 2008 Apr;40(3):752-4. doi: 10.1016/j.transproceed.2008.02.048.

PMID:
18455007
18.

Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy.

Kalil AC, Freifeld AG, Lyden ER, Stoner JA.

PLoS One. 2009;4(5):e5512. doi: 10.1371/journal.pone.0005512. Epub 2009 May 13.

19.

Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients.

Doesch AO, Repp J, Hofmann N, Erbel C, Frankenstein L, Gleissner CA, Schmidt C, Ruhparwar A, Zugck C, Schnitzler P, Ehlermann P, Dengler TJ, Katus HA.

Drug Des Devel Ther. 2012;6:289-95. doi: 10.2147/DDDT.S36578. Epub 2012 Oct 12.

20.

Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus.

Gruber SA, Garnick J, Morawski K, Sillix DH, West MS, Granger DK, El-Amm JM, Alangaden GJ, Chandrasekar P, Haririan A.

Clin Transplant. 2005 Apr;19(2):273-8.

PMID:
15740567

Supplemental Content

Support Center